104 related articles for article (PubMed ID: 8501580)
1. Single-dose pharmacokinetics and safety of HA-1A, a human IgM anti-lipid-A monoclonal antibody, in pediatric patients with sepsis syndrome.
Romano MJ; Kearns GL; Kaplan SL; Jacobs RF; Killian A; Bradley JS; Moss MM; Van Dyke R; Rodriguez W; Straube RC
J Pediatr; 1993 Jun; 122(6):974-81. PubMed ID: 8501580
[TBL] [Abstract][Full Text] [Related]
2. Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome.
Fisher CJ; Zimmerman J; Khazaeli MB; Albertson TE; Dellinger RP; Panacek EA; Foulke GE; Dating C; Smith CR; LoBuglio AF
Crit Care Med; 1990 Dec; 18(12):1311-5. PubMed ID: 2245602
[TBL] [Abstract][Full Text] [Related]
3. Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans.
Khazaeli MB; Wheeler R; Rogers K; Teng N; Ziegler E; Haynes A; Saleh MN; Hardin JM; Bolmer S; Cornett J
J Biol Response Mod; 1990 Apr; 9(2):178-84. PubMed ID: 2341860
[TBL] [Abstract][Full Text] [Related]
4. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
[TBL] [Abstract][Full Text] [Related]
5. HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
Smith CR; Straube RC; Ziegler EJ
Infect Dis Clin North Am; 1992 Mar; 6(1):253-66. PubMed ID: 1578120
[TBL] [Abstract][Full Text] [Related]
6. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
Barriere SL; Guglielmo BJ
Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
[TBL] [Abstract][Full Text] [Related]
7. Human monoclonal antibody against endotoxin.
Zarowitz BJ
DICP; 1991; 25(7-8):778-83. PubMed ID: 1949939
[TBL] [Abstract][Full Text] [Related]
8. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
[TBL] [Abstract][Full Text] [Related]
10. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.
McCloskey RV; Straube RC; Sanders C; Smith SM; Smith CR
Ann Intern Med; 1994 Jul; 121(1):1-5. PubMed ID: 8198341
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels.
Wortel CH; von der Möhlen MA; van Deventer SJ; Sprung CL; Jastremski M; Lubbers MJ; Smith CR; Allen IE; ten Cate JW
J Infect Dis; 1992 Dec; 166(6):1367-74. PubMed ID: 1431255
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
[TBL] [Abstract][Full Text] [Related]
14. Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide.
Bogard WC; Siegel SA; Leone AO; Damiano E; Shealy DJ; Ely TM; Frederick B; Mascelli MA; Siegel RC; Machielse B
J Immunol; 1993 May; 150(10):4438-49. PubMed ID: 7683319
[TBL] [Abstract][Full Text] [Related]
15. Limited sampling models for HA-1A IgM monoclonal antibody.
Hardin JM; Khazaeli MB; Allen IE; Dating C; LoBuglio AF
Hum Antibodies Hybridomas; 1990; 1(2):115-9. PubMed ID: 2103353
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis.
Quintiliani R; Cooper B; Maderazo E; Nightingale C
Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116
[TBL] [Abstract][Full Text] [Related]
17. GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.
Rasche L; Duell J; Castro IC; Dubljevic V; Chatterjee M; Knop S; Hensel F; Rosenwald A; Einsele H; Topp MS; Brändlein S
Haematologica; 2015 Mar; 100(3):377-84. PubMed ID: 25637055
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients.
Trang JM; LoBuglio AF; Wheeler RH; Harvey EB; Sun L; Ghrayeb J; Khazaeli MB
Pharm Res; 1990 Jun; 7(6):587-92. PubMed ID: 2367327
[TBL] [Abstract][Full Text] [Related]
19. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group.
Derkx B; Wittes J; McCloskey R
Clin Infect Dis; 1999 Apr; 28(4):770-7. PubMed ID: 10825037
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal anti-lipid A IgM antibodies HA-1A and E-5 recognize distinct epitopes on lipopolysaccharide and lipid A.
Fujihara Y; Bogard WC; Lei MG; Daddona PE; Morrison DC
J Infect Dis; 1993 Dec; 168(6):1429-35. PubMed ID: 7504034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
